BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-04
DOI
10.1002/cncr.33338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- (2020) Bruno Bockorny et al. NATURE MEDICINE
- The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
- (2017) M Abraham et al. LEUKEMIA
- Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia
- (2016) Shubhchintan Randhawa et al. BRITISH JOURNAL OF HAEMATOLOGY
- CXCR4Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group
- (2016) Hidemasa Matsuo et al. PEDIATRIC BLOOD & CANCER
- How I treat refractory and early relapsed acute myeloid leukemia
- (2015) F. Thol et al. BLOOD
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
- (2015) Farhad Ravandi et al. LANCET ONCOLOGY
- Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
- (2014) K. Beider et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
- (2013) K. Beider et al. CLINICAL CANCER RESEARCH
- The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
- (2013) A. Peled et al. CLINICAL CANCER RESEARCH
- CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia
- (2013) Ye Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
- (2012) G. L. Uy et al. BLOOD
- In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer
- (2012) Duha Fahham et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
- (2012) J J M van Dongen et al. LEUKEMIA
- CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
- (2010) Katia Beider et al. EXPERIMENTAL HEMATOLOGY
- Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
- (2009) F. Giles et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
- (2008) B. Nervi et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started